GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection.

Cheng Xiang FooStacey BartlettKeng Yih ChewMinh Dao NgoHelle Bielefeldt-OhmannBuddhika Jayakody ArachchigeBenjamin MatthewsSarah ReedRan WangChristian SmithMatthew J SweetLucy BurrKavita BishtSvetlana ShatunovaJane E SinclairRhys ParryYuanhao YangJean-Pierre LévesqueAlexander KhromykhMette Marie RosenkildeKirsty R ShortKatharina Ronacher

Published in: The European respiratory journal (2022)

GPR183 and provides the first preclinical evidence for therapeutic benefit of targeting GPR183 during severe viral respiratory infections.

Keyphrases

fatty acid
early onset
cancer therapy
stem cells
cell therapy
drug delivery
coronavirus disease